 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
|||||||||
| Faculty Name and Research Interest | |
 |
Janet Amico, MD Role of oxytocin in stress, anxiety, and ingestive behaviors. |
 |
Robert R. Bies, PharmD, PhD Development of heirarchical Bayesian approaches to understand nonlinearities in drug exposure and response. |
 |
Kim C. Coley, PharmD FCCP Factors that impact beneficial and adverse clinical outcomes to medications under conditions of usual care. |
 |
Tanya J. Fabian, PharmD, PhD Interaction between stress and mental and physical heath; genetic vulnerability to depression; prevention strategies. |
 |
Judith S. Gavaler, PhD Underlying causes for the substantial differences in life expectancy among racial\ethnic groups. |
 |
Sandra L. Kane-Gill, PharmD, MS, FCCM Evaluating the economic, clinical, and humanistic factors of drug therapy decision making for critically ill patients. |
 |
Levent Kirisci, PhD Development of instruments utilized in substance abuse; item response theory; mixed modeling; structural equation modeling. |
 |
Ada C. Mezzich, PhD Etiology of early onset substance abuse in high-risk children and young women. |
 |
Samuel M. Poloyac, PharmD, PhD Role of cytochrome P450 enzymes in the pathogenesis of neurotraumatic disease. |
 |
Lisa C. Rohan, PhD Design and development of drug delivery systems for STI/HIV prevention and gynecologic oncology applications. |
 |
Ralph E. Tarter, PhD Elucidating the interaction between biobehavioral and environmental factors underlying etiology of drug abuse and addiction. |
 |
Michael Vanyukov, PhD Genetic studies of substance-use disorders, antisociality, and associated traits. |
 |
Raman Venkataramanan, PhD Drug disposition in transplant patients; regulation of drug metabolism; drug metabolism and transport during pregnancy. |
 |
Jeffrey K Yao, PhD, FACB Application of metabolomics in psychosis and therapeutic monitoring. |
